| Malignant neoplasm of breast
Halaven vs Talzenna
Side-by-side clinical, coverage, and cost comparison for malignant neoplasm of breast.Deep comparison between: Halaven vs Talzenna with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTalzenna has a higher rate of injection site reactions vs Halaven based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Talzenna but not Halaven, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Halaven
Talzenna
At A Glance
IV infusion
Days 1 and 8 of a 21-day cycle
Microtubule dynamics inhibitor
Oral
Daily
PARP inhibitor
Indications
- Malignant neoplasm of breast
- Sarcoma
- Malignant neoplasm of breast
- Hormone refractory prostate cancer
Dosing
Malignant neoplasm of breast, Sarcoma 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle; reduce to 1.1 mg/m2 for mild hepatic impairment (Child-Pugh A) or moderate/severe renal impairment (CLcr 15-49 mL/min); reduce to 0.7 mg/m2 for moderate hepatic impairment (Child-Pugh B).
Malignant neoplasm of breast 1 mg orally once daily until disease progression or unacceptable toxicity.
Hormone refractory prostate cancer 0.5 mg orally once daily with enzalutamide until disease progression or unacceptable toxicity; patients should also receive a GnRH analog concurrently or have had bilateral orchiectomy.
Contraindications
—
—
Adverse Reactions
Most common (>=25%) - Metastatic breast cancer Neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, constipation
Most common (>=25%) - Liposarcoma and leiomyosarcoma Fatigue, nausea, alopecia, constipation, peripheral neuropathy, abdominal pain, pyrexia
Serious Febrile neutropenia, neutropenia
Postmarketing Lymphopenia, pancreatitis, hepatotoxicity, drug hypersensitivity, pneumonia, sepsis/neutropenic sepsis, interstitial lung disease, pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis
Most common (>=20%) Fatigue, nausea, vomiting, diarrhea, headache, alopecia, decreased appetite, hemoglobin decreased, neutrophils decreased, lymphocytes decreased, platelets decreased
Serious Anemia, pyrexia
Pharmacology
Eribulin mesylate is a microtubule dynamics inhibitor that inhibits the growth phase of microtubules, sequesters tubulin into nonproductive aggregates, and exerts antimitotic effects via G2/M cell-cycle block and disruption of mitotic spindles, ultimately leading to apoptotic cell death after prolonged mitotic blockage.
Talazoparib is an inhibitor of PARP enzymes (PARP1 and PARP2) involved in DNA repair; it induces cytotoxicity in cancer cells with DNA repair gene defects through inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes, resulting in DNA damage, decreased cell proliferation, and apoptosis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Halaven
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (0/12)
Talzenna
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (12/12)
UnitedHealthcare
Halaven
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Talzenna
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Halaven
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Talzenna
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Breast Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Talzenna.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
HalavenView full Halaven profile
TalzennaView full Talzenna profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.